Literature DB >> 26410136

Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury.

Trung C Nguyen1, Miguel A Cruz2, Joseph A Carcillo3.   

Abstract

Thrombocytopenia-associated multiple organ failure (TAMOF) is a clinical phenotype that encompasses a spectrum of syndromes associated with disseminated microvascular thromboses, such as the thrombotic microangiopathies thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) and disseminated intravascular coagulation (DIC). Autopsies findings in TTP, HUS, or DIC reveal specific findings that can differentiate these 3 entities. Von Willebrand factor and ADAMTS-13 play a central role in TTP. Shiga toxins and the complement pathway are vital in the development of HUS. Tissue factor is the major protease that drives the pathology of DIC. Acute kidney injury (AKI) is a common feature in patients with TAMOF.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADAMTS-13; AKI; DIC; HUS; Platelet; TAMOF; TTP; VWF

Mesh:

Substances:

Year:  2015        PMID: 26410136      PMCID: PMC5281060          DOI: 10.1016/j.ccc.2015.06.004

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  96 in total

1.  Eculizumab in severe Shiga-toxin-associated HUS.

Authors:  Anne-Laure Lapeyraque; Michal Malina; Véronique Fremeaux-Bacchi; Tobias Boppel; Michael Kirschfink; Mehdi Oualha; François Proulx; Marie-José Clermont; Françoise Le Deist; Patrick Niaudet; Franz Schaefer
Journal:  N Engl J Med       Date:  2011-05-25       Impact factor: 91.245

Review 2.  Shiga toxins--from cell biology to biomedical applications.

Authors:  Ludger Johannes; Winfried Römer
Journal:  Nat Rev Microbiol       Date:  2009-12-21       Impact factor: 60.633

3.  Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen.

Authors:  Y Asada; A Sumiyoshi; T Hayashi; J Suzumiya; K Kaketani
Journal:  Thromb Res       Date:  1985-06-01       Impact factor: 3.944

4.  Thrombocytopenia in a surgical ICU.

Authors:  F Stéphan; J Hollande; O Richard; A Cheffi; M Maier-Redelsperger; A Flahault
Journal:  Chest       Date:  1999-05       Impact factor: 9.410

5.  Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura.

Authors:  T W Chow; N A Turner; M Chintagumpala; P D McPherson; L H Nolasco; L Rice; J D Hellums; J L Moake
Journal:  Am J Hematol       Date:  1998-04       Impact factor: 10.047

6.  Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers.

Authors:  Maneesh Arya; Bahman Anvari; Gabriel M Romo; Miguel A Cruz; Jing-Fei Dong; Larry V McIntire; Joel L Moake; José A López
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

7.  A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation.

Authors:  Nobuo Aoki; Tamotsu Matsuda; Hidehiko Saito; Kiyoshi Takatsuki; Kenji Okajima; Hoyu Takahashi; Junki Takamatsu; Hidesaku Asakura; Nobuya Ogawa
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

Review 8.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

9.  Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study).

Authors:  Fabián Jaimes; Gisela De La Rosa; Carlos Morales; Fernando Fortich; Clara Arango; Daniel Aguirre; Alvaro Muñoz
Journal:  Crit Care Med       Date:  2009-04       Impact factor: 7.598

Review 10.  Biochemistry and genetics of von Willebrand factor.

Authors:  J E Sadler
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

View more
  19 in total

Review 1.  Assessing thrombocytopenia in the intensive care unit: the past, present, and future.

Authors:  Ryan Zarychanski; Donald S Houston
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

2.  Thrombotic microangiopathies in Pediatrics: current nomenclature and differential diagnoses with Thrombocytopenia-associated multiple organ failure (TAMOF).

Authors:  João Paulo Silva Cezar; Selma Harue Kawahara; Frederico Ribeiro Pires
Journal:  Rev Paul Pediatr       Date:  2021-12-20

3.  Genistein has the function of alleviating and treating disseminated intravascular coagulation caused by lipopolysaccharide.

Authors:  Xueqin Chen; Jingyi Tan; Mengqi Yang; Zhi-Kai Liao; Cheng Lu; Youwei Huang; Liang-Cai Wu
Journal:  J Nat Med       Date:  2018-05-14       Impact factor: 2.343

4.  A Multicenter Network Assessment of Three Inflammation Phenotypes in Pediatric Sepsis-Induced Multiple Organ Failure.

Authors:  Joseph A Carcillo; Robert A Berg; David Wessel; Murray Pollack; Kathleen Meert; Mark Hall; Christopher Newth; John C Lin; Allan Doctor; Tom Shanley; Tim Cornell; Rick E Harrison; Athena F Zuppa; Ron W Reeder; Russell Banks; John A Kellum; Richard Holubkov; Daniel A Notterman; J Michael Dean
Journal:  Pediatr Crit Care Med       Date:  2019-12       Impact factor: 3.624

5.  Therapeutic Plasma Exchange in Children With Thrombocytopenia-Associated Multiple Organ Failure: The Thrombocytopenia-Associated Multiple Organ Failure Network Prospective Experience.

Authors:  James D Fortenberry; Trung Nguyen; Jocelyn R Grunwell; Rajesh K Aneja; Derek Wheeler; Mark Hall; Geoffrey Fleming; Rod Tarrago; Sandra Buttram; Heidi Dalton; Yong Han; Kirk A Easley; Andrea Knezevic; Tian Dai; Matthew Paden; Joseph A Carcillo
Journal:  Crit Care Med       Date:  2019-03       Impact factor: 7.598

Review 6.  Understanding and treating solid tumor-related disseminated intravascular coagulation in the "era" of targeted cancer therapies.

Authors:  Felice Vito Vitale; Giuseppe Sa Longo-Sorbello; Stefano Rotondo; Francesco Ferrau
Journal:  SAGE Open Med       Date:  2017-12-21

7.  In vitro properties of concentrated canine platelets stored in two additive solutions: a comparative study.

Authors:  N Hlavac; C S Lasta; M L Dalmolin; L A Lacerda; D de Korte; N A Marcondes; S R Terra; F B Fernandes; F H D González
Journal:  BMC Vet Res       Date:  2017-11-15       Impact factor: 2.741

8.  Immune thrombocytopenia with multi-organ dysfunction syndrome as a rare presentation of scrub typhus: a case report.

Authors:  Abraham M Ittyachen; Saramma P Abraham; Smitha Krishnamoorthy; Anuroopa Vijayan; Jayamohan Kokkat
Journal:  BMC Res Notes       Date:  2017-10-06

Review 9.  Natural products as home-based prophylactic and symptom management agents in the setting of COVID-19.

Authors:  Sai Manohar Thota; Venkatesh Balan; Venketesh Sivaramakrishnan
Journal:  Phytother Res       Date:  2020-08-17       Impact factor: 6.388

10.  Recalibration of the Renal Angina Index for Pediatric Septic Shock.

Authors:  Natalja L Stanski; Hector R Wong; Rajit K Basu; Natalie Z Cvijanovich; Julie C Fitzgerald; Scott L Weiss; Michael T Bigham; Parag N Jain; Adam Schwarz; Riad Lutfi; Jeffrey Nowak; Geoffrey L Allen; Neal J Thomas; Jocelyn R Grunwell; Michael Quasney; Bereketeab Haileselassie; Lakhmir S Chawla; Stuart L Goldstein
Journal:  Kidney Int Rep       Date:  2021-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.